Exelixis beat Q1 EPS estimates on lower costs and share buybacks, but revenue missed expectations as Cabometyx sales came in below estimates. The print is mixed for the stock: profitability and capital returns are supportive, but the top-line and core product sales remain under pressure. Investors are now focused on pipeline progress and the company's new buyback activity.
Exelixis beat Q1 EPS estimates on lower costs and share buybacks, but revenue missed expectations as Cabometyx sales came in below estimates. The print is mixed for the stock: profitability and capital returns are supportive, but the top-line and core product sales remain under pressure. Investors are now focused on pipeline progress and the company's new buyback activity.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mixed
Sentiment Score
-0.10
Ticker Sentiment
